DAPAGLIFLOZIN
| Brand name | DAPAGLIFLOZIN |
|---|---|
| Active ingredient | DAPAGLIFLOZIN |
| Strength | 10MG |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | April 2026 |
| Marketing status | RX |
| Code | Expires |
|---|---|
| PC | October 2026 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.